Statistical software SPSS version 17.0 (SPSS inc., 233 South Wacker Drive, 11th floor, Chicago, IL, USA) trial was used for analysis
PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
This route delivers the peptide directly to inflamed skin and has shown improvements in plaque reduction and skin texture in early investigations
The reality that millions of people use these compounds despite the labeling creates an unusual market dynamic
You can read more about the trial here: Setria glutathione has also been shown to have a unique stability against stomach acid, making it impressively bioavailable
Who Uses BPC-157
